PCN48 Budget Impact Analysis of Fentanyl Buccal Tablet for the Treatment of Cancer Breaktrough Pain  by Darba, J. et al.
A400  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
prices fixed by negociation between the Comité Economique des Produits de Santé 
and the manufacturers. The average discount ranges from 11% to 73%. The aver-
age EMI varies between 1.42 and 2.69 € excluding value added tax (EVAT) per 1000 
international units and between 0.09 and 0.22 € EVAT per microgram according 
to the medicinal product. The average amount refunded to HF can be estimated 
at january 1, 2012 at 3.37 M€ , or 22.6% of the total budget. We assessed annual 
prices trends based on starting dates of contract, and we could figure out EMI 
trends. According to the product, the EMI quickly decline, remain broadly stable 
or increase. ConClusions: Many of top-selling biologics are due to lose patent 
protection over the next years. The emergence of competition in pharmaceutical 
market contributes to better control expenditure in our health system. The great 
potential for cost savings concerning erythropoietic factors in our study could be 
investigated in other class of medicinal products.
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objeCtives: To assess the economic impact of Fentanyl Buccal Tablet for the 
management of breakthrough cancer pain (BTcP) in Spain Methods: A 4-year 
budget impact model was developed for the period 2012-2015 for patients with 
BTcP from the perspective of the Spanish National Health System. BTcP products 
included in this model were rapid onset opioids containing fentanyl products 
(buccal, sublingual, or nasal transmucosal). Prevalence data on cancer, BTcP, opi-
oid use and number of BTcP episodes were obtained from literature. Input data 
on direct medical resources associated with opioid use and opioide-induced side 
effects (OISEs) were obtained by consulting experts in oncology from different 
Spanish hospitals. Resource utilisation included drugs, medical and emergency 
visits, other non-pharmacological treatments and the treatment of OISEs. Unit 
costs were obtained from literature and a 3% discount rate was applied to costs. 
Based on the unit costs for drugs and medical resources the annual BTcP treatment 
costs per patient associated with each product were determined, to estimate the 
overall budget impact based on the total treatment population and the percentage 
of drug utilisation associated with each product Results: Patients treated with 
oral opioids for BTcP was estimated at 23,291 in 2012 with an increase up to 23,413 
in 2015. The average annual budget savings with an increase of Fentanyl Buccal 
Tablet, Fentanyl Sublingual Tablet and Intranasal Fentanyl Spray and a decrease 
of Oral Transmucosal Fentanyl Citrate, was estimated at € 2.6 million over the 
next four years ConClusions: The increase in the use of Fentanyl Buccal Tablet 
leads to overall savings in the budget impact for the Spanish NHS. Although the 
economic impact of BTcP treatment showed to increase over the next four years 
due to population growth the average annual cost per patient reduced with € 29 
by the increase in the use of Fentanyl Buccal Tablet.
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objeCtives: To evaluate clinical and economic impact of increasing deno-
sumab use compared to zoledronic acid (ZA) in BrCa patients with BM to a 
MCO. Methods: An economic model was developed to estimate clinical and 
economic impact to a 1-million-member US MCO of introducing denosumab as 
bone-targeting agent (BTA) for prevention of SREs in BrCa patients with BM. Total 
number of patients receiving BTA was estimated based on disease prevalence and 
treatment eligibility in this population. The real-world SRE rates in ZA-treated 
patients were derived from a large commercial database and used together with 
the trial-based treatment effect for denosumab versus ZA to estimate the deno-
sumab SRE rate. Total number of SREs, total SRE management medical cost, BTA 
drug cost, and total cost were calculated. The impact of denosumab per-member-
per-month (PMPM) at increasing utilization rates was assessed by comparing to 
a scenario without denosumab, i.e., all patients received ZA. Additionally, impact 
of annual increase in denosumab use was conducted. Results: A total of 122 
BrCa patients with BM received BTA. In the scenario where all eligible patients 
receiving ZA, an annual total number of SREs was 155. An annual denosumab use 
of 20%, 35% or 45% resulted in 4.5%, 7.9%, and 10.2% reduction in total SREs and 
5.7%, 10.1%, and 12.9% reduction in medical costs of managing SREs, compared to 
all patients receiving ZA. The drug cost was partially offset by the reductions in 
the medical cost and the increase in total cost was minimal (2.4%-5.5%). The PMPM 
ranged $0.008-$0.017. Consecutive-year analysis showed $0.004 increase in PMPM 
with 10% denosumab utilization increase. ConClusions: Due to superior efficacy 
of denosumab versus ZA in SRE prevention in BrCa patients with BM, increased 
denosumab use results in medical cost reduction in a US MCO. Overall, denosumab 
provides additional clinical value with limited budget impact.
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objeCtives: Obinutuzumab is the first, glycoengineered type II antibody dem-
onstrating increased Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and 
background scenario the cost was 29,639.22€ . In terms of total costs the background 
scenario had a lower cost on average until the year 2009. ConClusions: Early detec-
tion of breast cancer improves survival prognosis and decreases treatment costs for 
each detected cancer. In the future, the costs of the early detection program will be 
balanced by the savings in treatment costs.
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objeCtives: Metastatic prostate cancer (MPC) results from the spread of cancer to 
distant parts of the body and is associated with markedly decreased survival. First 
line therapy for prostate cancer involves androgen deprivation, however most MPC 
patients progress in spite of castration levels of testosterone. A recently approved 
infusion product, Radium Ra 223 dichloride (Radium-223), has been introduced in 
the U.S. market adding to concerns about the costs for end-stage treatments. We 
sought to estimate the budget impact of Radium-223 on infusion center expenses 
in the U.S. Methods: We developed a financial model to estimate budget impact 
from a hospital-based infusion center perspective. Using data from the U.S. Census, 
SEER, and the Premier Perspective Database, we estimated the eligible population 
using a theoretical hospital’s catchment area. We modeled use, treatment costs 
and reimbursement for three radiopharmaceuticals (Radium-223, Samarium-153, 
and Strontium-89) and two common chemotherapies (docetaxel and cabazitazel) 
in terms of drug cost, infusions, and laboratory monitoring. Reimbursement for 
these treatments was estimated at both commercial and Medicare rates using the 
Average Sale Price and relevant Common Procedural Technology codes. We calcu-
lated total cost and reimbursement for one year with the current utilization from 
Premier and then estimated the incremental net budget impact associated with 
adoption of Radium-223 at 1, 3, and 5% of patients. Results: In a catchment area 
of 1 million lives, an estimated 45 MPC patients with non-visceral bone metastases 
would be treated with current agents and incur approximately $500,000 in treat-
ment costs for radiopharmaceuticals and chemotherapy. Adding Radium-223 to the 
treatment mix and assuming adoption rates of 1% to 5%, the annual net impact 
on the infusion center budget would range from $600 to $3,000. ConClusions: 
Radium-223 presents a new treatment option for MPC patients with non-visceral 
bone metastases and a positive net impact for infusion centers.
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objeCtives: Ovarian cancer (OC) is one of the most lethal gynecologic cancers 
worldwide. According to Brazilian Institute of Cancer (INCA), 6,190 new OC cases 
were estimated in 2012. During the last 15 years, carboplatin plus paclitaxel (CP) 
has been established as front-line (FL) standard of care therapy for advanced ovar-
ian cancer, with no significant advances in treatment ever since. Bevacizumab 
(Bev) in combination with CP was approved in Brazil for FL treatment of advanced 
epithelial OC on May/2013. Therefore, this study aimed to estimate the economic 
impact of bevacizumab reimbursement for advanced OC in Brazilian Supplementary 
Healthcare System. Methods: The potential number of eligible patients for CP + 
Bev in FL therapy for advanced OC was estimated following an epidemiologic 
approach. It was assumed that Supplementary Healthcare System attendance 
accounts for 40% of all patients. Additional drug costs and infusion fees were evalu-
ated. The ex-factory price (VAT 18%) and labeled dose were considered. Average 
therapy duration of CP + bevacizumab was 15 months based on GOG-0218 trial. Costs 
were reported in Brazilian Reais (BRL1.00≈USD0.44; Jun/2013). A total health assis-
tance budget of BRL 88.1 billion was forecasted for 2013, based on the last updated 
data from Brazilian National Regulatory Agency for Private Health Insurance and 
Plans (ANS). Results: A total of 1,287 eligible cases in CP + Bev FL therapy for 
advanced OC are expected in 2013 in the private setting. Adding bevacizumab to 
the treatment of all these potential patients would yield an increase of BRL 267 
million, corresponding only to an increment around 0.30% on health assistance 
expenses. ConClusions: Treating all eligible FL advanced OC patients with CP + 
Bev will potentially result in a low impact in Supplementary Healthcare System 
budget, associated to unprecedented clinical benefits for this population with a 
high medical unmet need.
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objeCtives: The patent expiries of leading biologic products and development of 
biosimilars create opportunities for cost saving. The french public health policies 
has established a complementary means encouraging heathcare facilities (HF) to 
save money : the ‘‘écart médicament indemnisable’’ (EMI). We explored the evalu-
ation of EMI on the erythropoietic factors class. Methods: We’ve carried out a 
comparative study in french HF, representing about 65% of national hospital beds, 
on the price of erythropoietic factors. The data have been collected on procurement 
procedures operative as at January 1, 2012. Results: A total of 25 care facilities or 
group of care facilities agreed to participate in the study. The overall sales turnover 
reached 15 millions euros (M€ ). All HF granted a discount from 5% to 69% on the 
